-
April 1, 2025Umecrine Cognition appoints Viktor Drvota as new CEOSTOCKHOLM – April 1, 2025. Umecrine Cognition today announces the appointment of Dr. Viktor Drvota as new Chief Executive Officer. He succeeds...
-
April 1, 2025Umecrine Cognition presents nonclinical data at AD/PD™ 2025 showing that golexanolone reverses dopamine loss and sustains improvements of Parkinsonian symptomsSTOCKHOLM – April 1, 2025. Umecrine Cognition today announces that the company will attend the 19th International Conference on...
-
March 18, 2025Umecrine Cognition provides update on the Phase 1b/2a clinical study of golexanoloneSTOCKHOLM – March 18, 2025. Umecrine Cognition today announces that its Phase 1b/2a study of golexanolone has been delayed due to technical issues...
Subscribe
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.